by European Public Health Alliance | Jun 30, 2022 | Universal Access and Affordable Medicines | Analysis & Opinion
By Dr Ward Rommel, Chair, Access to Medicines Task Force, Association of European Cancer Leagues (ECL) The research and innovation pathway for cancer medicines is challenging from basic research to market access. These challenges comprise high unmet needs, disparities...
by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion
Guest article Jaume Vidal, Senior Policy Advisor at Health Action International (HAI) In October 2020 in the midst of the COVID-19 pandemic, South Africa and India submitted a proposal to waiver certain dispositions of the Trade- Related aspects of Intellectual...
by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion
Guest article by Ancel·la Santos, Senior Health Policy Officer, The European Consumer Organisation (BEUC) To ensure recovery when facing health issues and a better quality of life among European citizens, it is essential that people get timely access to medicines and...
by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion
Guest article by Charlotte Roffiaen, European Policy Advisor at France Assos Santé For many years, the increasing prices of innovative medicines have focused the attention of the European public health community. Affordability issues were threatening both patient...
by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion
Article by Julia Aube, Policy Trainee for Healthcare Delivery The COVID-19 pandemic has jeopardised the access and availability of medicines in the EU, therefore, making the EU more resilient regarding the supply of pharmaceuticals is a key objective of...
by European Public Health Alliance | Apr 20, 2022 | Antimicrobial Resistance | Analysis & Opinion, COVID-19, Digital Health | Analysis & Opinion, Healthy Economic Policy | Analysis & Opinion, Non Communicable Diseases (NCDs), Universal Access and Affordable Medicines | Analysis & Opinion
The European Parliament is undertaking an extremely important task of examining how the European Union has dealt with the response to the ongoing COVID-19 pandemic. We know that its impact on almost every aspect of our lives and livelihoods has been and often...